Pharmacotherapy of non-small cell lung cancer

A short review

O. Balaji

Research output: Contribution to journalReview article

Abstract

Lung cancer is a global health problem with non-small cell lung cancer (NSCLC) being the most common histopathological variant causing almost 28% deaths in the United States of America. Platinum compounds were the mainstay of treatment, and since past 10 years, various newer targeted therapies have come into play. Epidermal growth factor receptor and anaplastic lymphoma kinase mutations play a major role in the development of advanced disease. Hence, targeted therapies and immunotherapies will remain an integral part in the management of advanced disease. Hence, this review focuses on the newer drugs approved by Food and Drug Administration to treat NSCLC.

Original languageEnglish
Pages (from-to)7-10
Number of pages4
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume11
Issue number3
DOIs
Publication statusPublished - 01-03-2018
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Platinum Compounds
United States Food and Drug Administration
Disease Management
Epidermal Growth Factor Receptor
Immunotherapy
Lung Neoplasms
Therapeutics
Mutation
Pharmaceutical Preparations
Global Health
anaplastic lymphoma kinase

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{d4173a4698214ed090ebbb8ff42daa5a,
title = "Pharmacotherapy of non-small cell lung cancer: A short review",
abstract = "Lung cancer is a global health problem with non-small cell lung cancer (NSCLC) being the most common histopathological variant causing almost 28{\%} deaths in the United States of America. Platinum compounds were the mainstay of treatment, and since past 10 years, various newer targeted therapies have come into play. Epidermal growth factor receptor and anaplastic lymphoma kinase mutations play a major role in the development of advanced disease. Hence, targeted therapies and immunotherapies will remain an integral part in the management of advanced disease. Hence, this review focuses on the newer drugs approved by Food and Drug Administration to treat NSCLC.",
author = "O. Balaji",
year = "2018",
month = "3",
day = "1",
doi = "10.22159/ajpcr.2018.v11i3.23253",
language = "English",
volume = "11",
pages = "7--10",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "3",

}

Pharmacotherapy of non-small cell lung cancer : A short review. / Balaji, O.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, No. 3, 01.03.2018, p. 7-10.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pharmacotherapy of non-small cell lung cancer

T2 - A short review

AU - Balaji, O.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Lung cancer is a global health problem with non-small cell lung cancer (NSCLC) being the most common histopathological variant causing almost 28% deaths in the United States of America. Platinum compounds were the mainstay of treatment, and since past 10 years, various newer targeted therapies have come into play. Epidermal growth factor receptor and anaplastic lymphoma kinase mutations play a major role in the development of advanced disease. Hence, targeted therapies and immunotherapies will remain an integral part in the management of advanced disease. Hence, this review focuses on the newer drugs approved by Food and Drug Administration to treat NSCLC.

AB - Lung cancer is a global health problem with non-small cell lung cancer (NSCLC) being the most common histopathological variant causing almost 28% deaths in the United States of America. Platinum compounds were the mainstay of treatment, and since past 10 years, various newer targeted therapies have come into play. Epidermal growth factor receptor and anaplastic lymphoma kinase mutations play a major role in the development of advanced disease. Hence, targeted therapies and immunotherapies will remain an integral part in the management of advanced disease. Hence, this review focuses on the newer drugs approved by Food and Drug Administration to treat NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85042908405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042908405&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2018.v11i3.23253

DO - 10.22159/ajpcr.2018.v11i3.23253

M3 - Review article

VL - 11

SP - 7

EP - 10

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 3

ER -